NEW YORK, Aug. 23 – Eli Lilly and Co. said it plans to acquire a 9 percent stake in Isis Pharmaceuticals in a $200 million, four-year deal in which it will license an antisense cancer compound being developed by Isis, and collaborate to use Isis' antisense technology to discover new drugs, the companies said.

Under the terms of the partnership, Lilly will pay $75 million, or $18 a share, for its stake in Isis, as well as $25 million to license ISIS 3521, the company’s promising antisense candidate for lung cancer.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers test gene therapy targeting a different cancer protein in a new trial, the New York Times reports.

Pennsylvania State University researchers found that salivary microRNAs could predict which kids would have longer concussion symptoms, according to NPR.

The Associated Press reports Alex Azar, the new Department of Health and Human Services secretary nominee, made millions of dollars as a pharmaceutical executive.

In PNAS this week: immune profiling of breast cancer, transposable element patterns in rice, and more.